Patents by Inventor Yoshiko Akamatsu

Yoshiko Akamatsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-4-1BB antibodies and their uses
    Patent number: 10875921
    Abstract: The present disclosure provides novel anti-4-1BB antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 29, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko Akamatsu, Jieyi Wang
  • ANTI-CD25 ANTIBODIES AND THEIR USES
    Publication number: 20200308290
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: June 11, 2020
    Publication date: October 1, 2020
    Inventors: Yoshiko AKAMATSU, Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
  • ANTI-4-1BB ANTIBODIES AND THEIR USES
    Publication number: 20190194329
    Abstract: The present disclosure provides novel anti-4-1BB antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Application
    Filed: May 26, 2017
    Publication date: June 27, 2019
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko AKAMATSU, Jieyi WANG
  • Bispecific binding proteins that bind CD40 and mesothelin
    Patent number: 10233258
    Abstract: The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: March 19, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko Akamatsu, Patricia Culp, Charles M. Forsyth, Ping Y. Huang, David Powers, Alan F. Wahl, Shiming Ye
  • BISPECIFIC BINDING PROTEINS
    Publication number: 20180194862
    Abstract: The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 12, 2018
    Inventors: Yoshiko AKAMATSU, Patricia CULP, Charles M. FORSYTH, Ping Y. HUANG, David POWERS, Alan F. WAHL, Shiming YE
  • BISPECIFIC BINDING PROTEINS
    Publication number: 20170342169
    Abstract: The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Inventors: Yoshiko AKAMATSU, Patricia Culp, Charles M. Forsyth, Ping Y. Huang, David Powers, Alan F. Wahl, Shiming Ye
  • Anti-VEGF antibodies and their uses
    Patent number: 9815893
    Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: November 14, 2017
    Assignee: AbbVie Biotherapeutics Inc.
    Inventor: Yoshiko Akamatsu
  • ANTI-CD25 ANTIBODIES AND THEIR USES
    Publication number: 20170233481
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: May 3, 2017
    Publication date: August 17, 2017
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko AKAMATSU, Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
  • CTLA4 proteins and their uses
    Patent number: 9587007
    Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: March 7, 2017
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko Akamatsu, Veronica Juan, Robert B. Dubridge
  • Anti-TNF-alpha antibodies and their uses
    Patent number: 9315573
    Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: April 19, 2016
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
  • ANTI-VEGF ANTIBODIES AND THEIR USES
    Publication number: 20150299307
    Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.
    Type: Application
    Filed: November 27, 2013
    Publication date: October 22, 2015
    Inventor: Yoshiko AKAMATSU
  • Anti-VEGF antibodies and their uses
    Patent number: 9079953
    Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: July 14, 2015
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. DuBridge, David B. Powers
  • CTLA4 PROTEINS AND THEIR USES
    Publication number: 20150051158
    Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 19, 2015
    Inventors: Yoshiko AKAMATSU, Veronica Juan, Robert B. Dubridge
  • Anti-HER2 antibodies and their uses
    Patent number: 8937159
    Abstract: The present disclosure relates to antibodies directed to HER2 and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of HER2.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: January 20, 2015
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
  • ANTI-CD25 ANTIBODIES AND THEIR USES
    Publication number: 20150010539
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 8, 2015
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING, PAUL R. HINTON, MENGLI XIONG, OLIVIA JENNIFER RAZO, SHIMING YE
  • ANTI-CD25 ANTIBODIES AND THEIR USES
    Publication number: 20150010538
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 8, 2015
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING
  • CTLA4 proteins and their uses
    Patent number: 8883971
    Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: November 11, 2014
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko Akamatsu, Veronica Juan, Robert B. Dubridge
  • ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES
    Publication number: 20140212424
    Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.
    Type: Application
    Filed: February 28, 2014
    Publication date: July 31, 2014
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
  • ANTI-VEGF ANTIBODIES AND THEIR USES
    Publication number: 20140154255
    Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.
    Type: Application
    Filed: November 26, 2013
    Publication date: June 5, 2014
    Applicant: AbbVie Biotherapeutics Inc.
    Inventor: Yoshiko AKAMATSU
  • Anti-TNF-? antibodies and their uses
    Patent number: 8722860
    Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: May 13, 2014
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers